KOMZIFTI

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Nov 13, 2025

   7 mo ago

2. Today

3. Exclusivity ends · NCE

   New chemical entity exclusivity (5 years)

   Nov 13, 2030

   in 4 yr 6 mo

4. Patent 10077271 expires

   Listed drug substance patent expiration.

   Mar 16, 2036

   in 9 yr 11 mo

5. Patent 10174041 expires

   Listed method-of-use patent (U-4350) expiration.

   Mar 16, 2036

   in 9 yr 11 mo

6. Patent 10174041 expires

   Listed method-of-use patent (U-4354) expiration.

   Mar 16, 2036

   in 9 yr 11 mo

7. Patent 10869868 expires

   Listed method-of-use patent (U-4352) expiration.

   Jan 26, 2037

   in 10 yr 9 mo

8. Patent 10869868 expires

   Listed method-of-use patent (U-4353) expiration.

   Jan 26, 2037

   in 10 yr 9 mo

9. Patent 10781218 expires

   Listed drug substance patent expiration.

   Mar 15, 2037

   in 10 yr 11 mo

10. Patent 11673898 expires

    Listed method-of-use patent (U-4350) expiration.

    Mar 15, 2037

    in 10 yr 11 mo

11. Patent 11673898 expires

    Listed method-of-use patent (U-4351) expiration.

    Mar 15, 2037

    in 10 yr 11 mo

12. Patent 11944627 expires

    Listed method-of-use patent (U-4347) expiration.

    Sep 06, 2038

    in 12 yr 5 mo

13. Patent 11944627 expires

    Listed method-of-use patent (U-4349) expiration.

    Sep 06, 2038

    in 12 yr 5 mo

14. Patent 12410184 expires

    Listed drug substance patent expiration.

    Jul 16, 2044

    in 18 yr 4 mo

15. Patent 12410184 expires

    Listed drug substance patent expiration.

    Jul 16, 2044

    in 18 yr 4 mo

16. Patent 12521396 expires

    Listed drug product patent expiration.

    Jul 16, 2044

    in 18 yr 4 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (1)

• NCENew chemical entity exclusivity (5 years)

  Nov 13, 2030

  in 4 yr 6 mo

Listed patents (13)